臨床外科78巻12号

2023年11月発行

特集 胃癌に対するconversion surgery—Stage Ⅳでも治したい！ Topic

Conversion surgeryは本当に必要か？—MSI-H/dMMR症例における臓器温存の可能性

著者： 榊田智喜¹ 舛石俊樹¹ 室圭¹

所属機関： ¹愛知県がんセンター薬物療法部

ページ範囲：P.1375 - P.1379

【ポイント】
◆MSI-H/dMMR切除可能胃癌に対する術前免疫チェックポイント阻害薬（ICI）は病理学的完全奏効（pCR）割合が高い．
◆MSI-H/dMMR切除不能胃癌に対するICIは高い奏効割合と長期生存が期待できる．
◆切除可能・不能にかかわらずMSI-H/dMMR胃癌に対するICIにより，手術回避による臓器温存が選択肢となる可能性がある．

参考文献

1）Cancer Genome Atlas Resparch Network：Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513：202-209, 2014

2）Le DT, Durham JN, Smith KN, et al：Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357：409-413, 2017

3）Komori A, Hironaka S, Yoshimura K, et al：Clinicopathological features of MSI-high unresectable chemo-naïve advanced gastric cancer：an interim analysis of WJOG13320GPS. The 94th Annual Meeting of the Japanese Gastric Cancer Association. Yokohama, Japan, Mar 2022

4）Pietrantonio F, Miceli R, Raimondi A, et al：Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer. J Clin Oncol 37：3392-3400, 2019

5）Polom K, Marrelli D, Roviello G, et al：Molecular key to understand the gastric cancer biology in elderly patients-The role of microsatellite instability. J Surg Oncol 115：344-350, 2017

6）Smyth EC, Wotherspoon A, Peckitt C, et al：Mismatch repair deficiency, microsatellite instability, and survival：an exploratory analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy（MAGIC）trial. JAMA Oncol 3：1197-1203, 2017

7）Al-Batran SE, Lorenzen S, Thuss-Patience P, et al：Surgical and pathological outcome in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy vs. FLOT alone for resectable esophagogastric adenocarcinoma：interim results from DANTE, a randomized, multicenter, phaseⅡb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK. The 2022 American Society of Clinical Oncology（ASCO）Annual Meeting. Chicago, IL, USA, Jun 2022

8）André T, Tougeron D, Piessen G, et al：Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma：the GERCOR NEONIPIGA phase Ⅱ study. J Clin Oncol 41：255-265, 2023

9）Pietrantonio F, Raimondi A, Lonardi S, et al：Multicentre, single-arm, multi-cohort, phase Ⅱ trial of tremelimumab and durvalumab as neoadjvant treatment of patients with microsatellite instability-high（MSI-H）resectable gastric or gastroesophageal junction adenocarcinoma：the INFINITY study by GONO. The 2023 American Society of Clinical Oncology（ASCO）Gastrointestinal（GI）Cancers Symposium. San Francisco, CA, USA, Jan 2023

10）Haag GM, Czink E, Ahadova A, et al：Prognostic significance of microsatellite-instability in gastric and gastroesophageal junction cancer patients undergoing neoadjuvant chemotherapy. Int J Cancer 144：1697-1703, 2019

11）Li Z, Wang Y, Ying X, et al：Prognostic and predictive value of mismatch repair deficiency in gastric and gastroesophageal junction adenocarcinoma patients receiving neoadjuvant or adjuvant chemotherapy. J Surg Oncol 124：1356-1364, 2021

12）Marabelle A, Le DT, Ascierto PA, et al：Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer：results from the phase Ⅱ KEYNOTE-158 Study. J Clin Oncol 38：1-10, 2020

13）Chao J, Fuchs CS, Shitara K, et al：Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials. JAMA Oncol 7：895-902, 2021

14）Janjigian YY, Shitara K, Moehler M, et al：First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma（CheckMate 649）：a randomised, open-label, phase 3 trial. Lancet 398：27-40, 2021

15）Shitara K, Ajani JA, Moehler M, et al：Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature 603：942-948, 2022

16）Kawakami H, Hironaka S, Esaki T, et al：An investigator-initiated phase 2 study of nivolumab plus low-dose ipilimumab as first-line therapy for microsatellite instability-high advanced gastric or esophagogastric junction cancer（NO LIMIT, WJOG13320G/CA209-7W7）. Cancers（Basel）13：805, 2021

17）Hidaka Y, Arigami T, Osako Y, et al：Conversion surgery for microsatellite instability-high gastric cancer with a complete pathological response to pembrolizumab：a case report. World J Surg Oncol 20：193, 2022

18）Jian D, Qian C, Wang D, et al：Conversion therapy with tislelizumab for high microsatellite instability, unresectable stage Ⅲ gastric cancer：a case report. Ann Transl Med 9：1489, 2021

19）畑中一映，早坂秀平，土田直央，他：Nivolumabが著効しConversion Surgeryを施行後完全奏効が確認された胃癌の1例．道南医会ジャーナル3：18-22, 2020

20）山井礼道，清水茂翔，南城和正，他：Pembrolizumabが著効し，膵頭十二指腸切除術，門脈合併切除にてpCRを確認した切除不能胃癌の1例．高知赤十字病医誌26：37-40, 2021